Personalized and targeted therapies

被引：0
作者：
Wisniewska, Magdalena [3 ,4 ]
Wisniewski, Michal [5 ]
Lewandowska, Marzena A. [1 ,2 ]
机构：
[1] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Dept Thorac Surg & Tumors, Torun, Poland
[2] Innovat Med Forum Oncol Ctr, Dept Mol Oncol & Genet, Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Dept Oncol & Brachytherapy, Torun, Poland
[4] Oncol Ctr, Dept Clin Oncol, Bydgoszcz, Poland
[5] Oncol Ctr, Outpatient Chemotherapy Dept, Bydgoszcz, Poland
来源：
PHYSICAL SCIENCES REVIEWS | 2021年
关键词：
biomarker; predictive biomarkers; tailored treatment; targeted therapies; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; ANAPLASTIC LYMPHOMA KINASE; GROWTH-FACTOR RECEPTOR; WILD-TYPE KRAS; BREAST-CANCER; OPEN-LABEL; RAS MUTATIONS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY;
D O I：
10.1515/psr-2019-0057
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Biomarker is defined as indicator of normal or pathogenic biological process or response to an intervention or exposure. There are several categories of biomarkers but predictive biomarkers play the most important role in the treatment of neoplasms. In some cancers there may be more than one potential biomarker, and their identification determines the treatment of the patient. Identification of predictive biomarkers allows the development of novel targeted therapies resulting in tailored treatment. In this chapter we discuss most important predictive biomarkers used in contemporary oncology for which there is approved therapies.
引用
收藏
页码：2103 / 2126
页数：24
相关论文
共 120 条
  • [21] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
    Doebele, Robert C.
    Drilon, Alexander
    Paz-Ares, Luis
    Siena, Salvatore
    Shaw, Alice T.
    Farago, Anna F.
    Blakely, Collin M.
    Seto, Takashi
    Cho, Byung Chul
    Tosi, Diego
    Besse, Benjamin
    Chawla, Sant P.
    Bazhenova, Lyudmila
    Krauss, John C.
    Chae, Young Kwang
    Barve, Minal
    Garrido-Laguna, Ignacio
    Liu, Stephen V.
    Conkling, Paul
    John, Thomas
    Fakih, Marwan
    Sigal, Darren
    Loong, Herbert H.
    Buchschacher, Gary L., Jr.
    Garrido, Pilar
    Nieva, Jorge
    Steuer, Conor
    Overbeck, Tobias R.
    Bowles, Daniel W.
    Fox, Elizabeth
    Riehl, Todd
    Chow-Maneval, Edna
    Simmons, Brian
    Cui, Na
    Johnson, Ann
    Eng, Susan
    Wilson, Timothy R.
    Demetri, George D.
    [J]. LANCET ONCOLOGY, 2020, 21 (02) : 271 - 282
  • [22] Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
    Douillard, Jean-Yves
    Oliner, Kelly S.
    Siena, Salvatore
    Tabernero, Josep
    Burkes, Ronald
    Barugel, Mario
    Humblet, Yves
    Bodoky, Gyorgy
    Cunningham, David
    Jassem, Jacek
    Rivera, Fernando
    Kocakova, Ilona
    Ruff, Paul
    Blasinska-Morawiec, Maria
    Smakal, Martin
    Canon, Jean Luc
    Rother, Mark
    Williams, Richard
    Rong, Alan
    Wiezorek, Jeffrey
    Sidhu, Roger
    Patterson, Scott D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) : 1023 - 1034
  • [23] Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
    Drilon, A.
    Oxnard, G.
    Wirth, L.
    Besse, B.
    Gautschi, O.
    Tan, S. W. D.
    Loong, H.
    Bauer, T.
    Kim, Y. J.
    Horiike, A.
    Park, K.
    Shah, M.
    McCoach, C.
    Bazhenova, L.
    Seto, T.
    Brose, M.
    Pennell, N.
    Weiss, J.
    Matos, I.
    Peled, N.
    Cho, B. C.
    Ohe, Y.
    Reckamp, K.
    Boni, V.
    Satouchi, M.
    Falchook, G.
    Akerley, W.
    Daga, H.
    Sakamoto, T.
    Patel, J.
    Lakhani, N.
    Barlesi, F.
    Burkard, M.
    Zhu, V.
    Garcia, V. Moreno
    Medioni, J.
    Matrana, M.
    Rolfo, C.
    Lee, D. H.
    Nechushtan, H.
    Johnson, M.
    Velcheti, V.
    Nishio, M.
    Toyozawa, R.
    Ohashi, K.
    Song, L.
    Han, J.
    Spira, A.
    De Braud, F.
    Rohrberg, K. Staal
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S6 - S7
  • [24] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
    Drilon, A.
    Laetsch, T. W.
    Kummar, S.
    DuBois, S. G.
    Lassen, U. N.
    Demetri, G. D.
    Nathenson, M.
    Doebele, R. C.
    Farago, A. F.
    Pappo, A. S.
    Turpin, B.
    Dowlati, A.
    Brose, M. S.
    Mascarenhas, L.
    Federman, N.
    Berlin, J.
    El-Deiry, W. S.
    Baik, C.
    Deeken, J.
    Boni, V.
    Nagasubramanian, R.
    Taylor, M.
    Rudzinski, E. R.
    Meric-Bernstam, F.
    Sohal, D. P. S.
    Ma, P. C.
    Raez, L. E.
    Hechtman, J. F.
    Benayed, R.
    Ladanyi, M.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Hawkins, D. S.
    Hong, D. S.
    Hyman, D. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) : 731 - 739
  • [25] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
    Drilon, Alexander
    Siena, Salvatore
    Dziadziuszko, Rafal
    Barlesi, Fabrice
    Krebs, Matthew G.
    Shaw, Alice T.
    de Braud, Filippo
    Rolfo, Christian
    Ahn, Myung-Ju
    Wolf, Juergen
    Seto, Takashi
    Cho, Byoung Chul
    Patel, Manish R.
    Chiu, Chao-Hua
    John, Thomas
    Goto, Koichi
    Karapetis, Christos S.
    Arkenau, Hendrick-Tobias
    Kim, Sang-We
    Ohe, Yuichiro
    Li, Yu-Chung
    Chae, Young K.
    Chung, Christine H.
    Otterson, Gregory A.
    Murakami, Haruyasu
    Lin, Chia-Chi
    Tan, Daniel S. W.
    Prenen, Hans
    Riehl, Todd
    Chow-Maneval, Edna
    Simmons, Brian
    Cui, Na
    Johnson, Ann
    Eng, Susan
    Wilson, Timothy R.
    Doebele, Robert C.
    [J]. LANCET ONCOLOGY, 2020, 21 (02) : 261 - 270
  • [26] Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Drilon, Alexander
    Rekhtman, Natasha
    Arcila, Maria
    Wang, Lu
    Ni, Andy
    Albano, Melanie
    Van Voorthuysen, Martine
    Somwar, Romel
    Smith, Roger S.
    Montecalvo, Joseph
    Plodkowski, Andrew
    Ginsberg, Michelle S.
    Riely, Gregory J.
    Rudin, Charles M.
    Ladanyi, Marc
    Kris, Mark G.
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1653 - 1660
  • [27] The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
    Ducray, Stephen P.
    Natarajan, Karthikraj
    Garland, Gavin D.
    Turner, Suzanne D.
    Egger, Gerda
    [J]. CANCERS, 2019, 11 (08)
  • [28] Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion
    Farago, Anna F.
    Taylor, Martin S.
    Doebele, Robert C.
    Zhu, Viola W.
    Kummar, Shivaani
    Spira, Alexander, I
    Boyle, Theresa A.
    Haura, Eric B.
    Arcila, Maria E.
    Benayed, Ryma
    Aisner, Dara L.
    Horick, Nora K.
    Lennerz, Jochen K.
    Le, Long P.
    Iafrate, A. John
    Ou, Sai-Hong, I
    Shaw, Alice T.
    Mino-Kenudson, Mari
    Drilon, Alexander
    [J]. JCO PRECISION ONCOLOGY, 2018, 2
  • [29] FDA-NIH Biomarker Working Group, 2016, BEST BIOM ENDPOINTS
  • [30] Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer
    Ferrara, Roberto
    Auger, Nathalie
    Auclin, Edouard
    Besse, Benjamin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (01) : 27 - 45
12345678910